Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

New treatment combinations and targeted therapies for lymphoma and multiple myeloma are improving outcomes for vulnerable patient populations with hard-to-treat disease, according to studies presented today at the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

Findings may guide doctors to choose better therapies for patients with myeloma

The "molecular mail" sent by multiple myeloma cells provides clues to how well patients with the disease are likely to respond to treatment, according to a study being presented at the annual meeting of the American Society of Hematology by researchers at Dana-Farber Cancer Institute.

7 Dec 2014

Innovative cell therapy shows highly promising results in pediatric patients with ALL

An innovative cell therapy against a highly aggressive form of acute lymphoblastic leukemia (ALL) continues to show highly promising results in children treated in a pilot study. Ninety-two percent of the 39 children receiving bioengineered T cells had no evidence of cancer at one month after treatment, with this complete response persisting in some cases for more than two years.

7 Dec 2014

MorphoSys, Xencor announce final results from MOR208 Phase 1/2a trial in patients with CLL/SLL

MorphoSys AG and Xencor Inc. today announced the publication of final results of a Phase 1/2a trial evaluating MOR208 (formerly XmAb5574) in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL).

7 Dec 2014

IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

New IMBRUVICA (ibrutinib) Phase II data announced here today by Pharmacyclics, Inc) during the 56th American Society of Hematology Annual Meeting suggests that IMBRUVICA demonstrates anti-tumor activity both as a single-agent and as combination therapy in heavily pre-treated patients with relapsed or relapsed/refractory multiple myeloma (MM).

7 Dec 2014

Novel treatments show safe responses in patients with relapsed, treatment-resistant blood cancers

Novel treatments that harness the body's own immune cells to attack cancer cells demonstrate safe and durable responses in patients with relapsed and treatment-resistant blood cancers, according to data presented today at the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

Comb-shaped polymers efficiently protect proteins in vivo

An enzyme that usually triggers strong allergic reactions now circulates in the veins of a group of mice without alerting the immune system. As INRS Énergie Matériaux Télécommunications Research Centre Professor Marc A. Gauthier explains in an article published in the journal Nature Communications, a polymer was used to camouflage the enzyme before it was injected into the rodents. This was achieved by coating the enzyme to avoid an immune response in a manner that does not compromise its activity.

6 Dec 2014

Pharmacyclics launches informCLL registry to explore natural history of CLL patients

Pharmacyclics, Inc. today announced the launch of informCLL, a large, observational, prospective registry that will explore the natural history of chronic lymphocytic leukemia (CLL), examine how IMBRUVICA (ibrutinib) and other approved targeted therapies are being used to treat patients with CLL, and provide a comparison to treatments using conventional chemoimmunotherapy (CIT).

5 Dec 2014

Pharmacyclics wins 2014 Society for Medicines Research Award for Drug Discovery

Pharmacyclics, Inc. today announced that it has won the prestigious 2014 Society for Medicines Research Award for Drug Discovery for its discovery of ibrutinib (IMBRUVICA). The award was presented by The Society of Medicines Research at its biennial award lecture in Kensington, London.

4 Dec 2014

Novartis to highlight advances in blood, breast cancer research at ASH and SABCS 2014

Novartis will highlight more than 250 abstracts demonstrating advances in blood and breast cancer research at the upcoming American Society of Hematology (ASH) annual meeting December 6-9, and CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) December 9-13.

2 Dec 2014

Scientists investigate Veto Cell technology to treat blood cancers, bone marrow transplants

Overcoming graft rejection is the main obstacle when it comes to stem cell regeneration or organ transplantation.

2 Dec 2014

U of T professor wins GSK's 2014 Discovery Fast Track Challenge devoted for cancer research

University of Toronto (U of T) Professor Tania Watts is a winner of GSK's 2014 Discovery Fast Track Challenge, which is designed to accelerate the translation of academic research into novel therapies.

2 Dec 2014

EMA accepts new IMBRUVICA (ibrutinib) application for treatment of Waldenstrom's macroglobulinemia

Pharmacyclics, Inc.today announced the acceptance of a Type II variation application for IMBRUVICA (ibrutinib) by the European Medicines Agency.

1 Dec 2014

CTI BioPharma announces upcoming presentations of pacritinib data at ASH Annual Meeting

CTI BioPharma Corp. (CTI) today announced the upcoming presentations of data highlighting pacritinib, an oral multikinase inhibitor with dual activity against JAK2 and FLT3, and tosedostat, an oral selective inhibitor of aminopeptidases, at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 6-9 in San Francisco, CA.

1 Dec 2014

Researchers identify key molecule that drives excess protein production in Fragile X patients' brain

People affected by a common inherited form of autism could be helped by a drug that is being tested as a treatment for cancer.

27 Nov 2014

Researchers uncover easily detectable, 'pre-malignant' state in the blood

Researchers from the Broad Institute of MIT and Harvard, Harvard Medical School, and Harvard-affiliated hospitals have uncovered an easily detectable, "pre-malignant" state in the blood that significantly increases the likelihood that an individual will go on to develop blood cancers such as leukemia, lymphoma, or myelodysplastic syndrome.

27 Nov 2014

Oxford BioTherapeutics, Menarini Group initiate phase I study of OBT357 (MEN1112) for AML treatment

Oxford BioTherapeutics and Berlin Chemie/ Menarini Biotech/ Menarini Ricerche (belonging to Menarini Group) announce today that they have initiated the first-in-human clinical study of OBT357 (MEN1112), a novel enhanced antibody for the treatment of acute myeloid leukemia (AML).

25 Nov 2014

MD Anderson study sheds light on little-known protein complex

A study at The University of Texas MD Anderson Cancer Center led by Mong-Hong Lee, Ph.D., a professor of molecular and cellular oncology, has demonstrated the significance of CSN6 in regulating Myc which may very well open up a new pathway for treating and killing tumors.

21 Nov 2014

Alliance for Balanced Pain Management established to support appropriate access to pain management

A diverse collective of health care advocacy groups, patient organizations, industry representatives and other stakeholders today announced they have established the Alliance for Balanced Pain Management (AfBPM) to support appropriate access to integrated pain management and responsible use of prescription pain medicines with an aim to reduce abuse.

21 Nov 2014

BerGenBio's BGB324 gets orphan-drug designation from FDA for AML treatment

BerGenBio AS, an oncology biopharmaceutical company, today announces that the US Food and Drug Administration has granted orphan-drug designation for BGB324 for treatment of acute myeloid leukaemia (AML).

19 Nov 2014

Leukemia News and Research

Further Reading

New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

Findings may guide doctors to choose better therapies for patients with myeloma

Innovative cell therapy shows highly promising results in pediatric patients with ALL

MorphoSys, Xencor announce final results from MOR208 Phase 1/2a trial in patients with CLL/SLL

IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

Novel treatments show safe responses in patients with relapsed, treatment-resistant blood cancers

Comb-shaped polymers efficiently protect proteins in vivo

Pharmacyclics launches informCLL registry to explore natural history of CLL patients

Pharmacyclics wins 2014 Society for Medicines Research Award for Drug Discovery

Novartis to highlight advances in blood, breast cancer research at ASH and SABCS 2014

Scientists investigate Veto Cell technology to treat blood cancers, bone marrow transplants

U of T professor wins GSK's 2014 Discovery Fast Track Challenge devoted for cancer research

EMA accepts new IMBRUVICA (ibrutinib) application for treatment of Waldenstrom's macroglobulinemia

CTI BioPharma announces upcoming presentations of pacritinib data at ASH Annual Meeting

Researchers identify key molecule that drives excess protein production in Fragile X patients' brain

Researchers uncover easily detectable, 'pre-malignant' state in the blood

Oxford BioTherapeutics, Menarini Group initiate phase I study of OBT357 (MEN1112) for AML treatment

MD Anderson study sheds light on little-known protein complex

Alliance for Balanced Pain Management established to support appropriate access to pain management

BerGenBio's BGB324 gets orphan-drug designation from FDA for AML treatment

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News